OptimizeRx Appoints Greg Wasson, Former President and CEO of Walgreens Boots Alliance, to Its Board of Directors
2020年7月21日 - 8:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has
appointed Greg Wasson, former president and CEO of Walgreen Boots
Alliance, to its board of directors.
“Consumer awareness of digital health services, and especially
the need for better affordability and adherence, has never been
greater,” said OptimizeRx CEO and director, William Febbo. “Our
platform delivers for the life sciences industry unprecedented
access to physicians and patients at the point-of-care. Staying
connected with the patient as they enter a physical or virtual
pharmacy now presents another important area of opportunity to
deliver value to our stakeholders. In light of this, Greg’s
experience in building Walgreens as a Fortune 50 company with
global reach makes him an exceptionally valuable and timely
addition to our board as we look to enhance patient connectivity at
the point-of-dispense.”
As president and CEO of Walgreens, Wasson led the company to
record sales of $76.4 billion in 2014. He created significant
shareholder value by completing game-changing mergers and
acquisitions, leading complex organizational and structural change,
assembling a diverse and high-performance senior leadership team,
and establishing Walgreens as an industry leader. Wasson is largely
credited for transforming the iconic 114-year-old domestic company
into the first global pharmacy-led, health, well-being, and beauty
enterprise via the successful merger with European-based Alliance
Boots in 2015.
Prior to being appointed president and CEO of the combined
companies, Walgreens Boots Alliance, Wasson had risen through the
ranks through a number of positions of increasing responsibility
and executive leadership, starting as a Walgreens pharmacist
technician in 1981.
Commented Wasson: “Having been fortunate to serve the industry
for so many years and in a variety of roles, from pharmacist to
CEO, I’ve gained a deep understanding of the profession of pharmacy
and value it brings to our healthcare system. I believe there is
real opportunity to create more affordability and better adherence
to medication and treatments utilizing digital tools at
point-of-dispense. I look forward to working with Will and his team
as we bring the benefits of the OptimizeRx digital health platform
to this critical area of care.”
Subsequent to Walgreens, Wasson has been involved in a number of
successful businesses. He currently serves as president of Wasson
Enterprise, a family office committed to building sustainable,
high-growth businesses that do well by doing good.
Wasson also currently serves on the boards of Health Care
Service Corporation and Performance Health Systems, and as the
executive chairman of Innovation Associates. He was the co-founder
and currently serves on the boards of Cooler Screens, Golden Fleece
Beverages, and Innventure.
In 2015, Wasson received the Sheldon W. Fantle Lifetime
Achievement Award from the National Association of Chain Drug
Stores, and the GMA Hall of Achievement Award from the Grocery
Manufacturers Association. In 2016, he was honored with the
Distinguished Alumni Award and Career Achievement Award from Purdue
University, where he earned his Bachelor of Science in Pharmacy in
1981.
About OptimizeRxOptimizeRx Corporation (NASDAQ:
OPRX) is a digital health company that facilitates communication at
the point-of-care among all stakeholders in healthcare. Primarily
focused on life science and payer clients, its suite of digital and
mobile SaaS-based solutions enables affordability, patient
adherence and care management. OptimizeRx’s network reaches more
than 60% of U.S. ambulatory providers, delivering therapeutic
support on specialty medications and patient financial assistance
directly within a provider’s workflow through leading electronic
health platforms. OptimizeRx’s fully integrated platform supports
the real-time exchange of information, improving provider knowledge
and patient engagement, and ultimately leading to healthier
outcomes. For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra, Media
Relations ManagerTel (754) 245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both or Grant
StudeCMA Investor RelationsTel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024